DPP-IV inhibitors could be cost-effective for T2DM
1
PharmacoEconomics & Outcomes News 556 - 28 Jun 2008 DPP-IV inhibitors could be cost- effective for T2DM Because of the potential for DPP-IV inhibitors [CD-26 antigen agonists] to preserve β-cell function, US-based researchers evaluated the 35-year cost effectiveness of a hypothetical DPP-IV inhibitor versus no treatment, in patients with type 2 diabetes. Their findings were presented at the 68th Annual Scientific Sessions of the American Diabetes Association A mean baseline HbA 1c of 7.6% was assumed in the base case simulation, with a reduction in HbA 1c of 0.6% for the DPP-IV inhibitor but no improvement with no treatment. β-cell function decay curves of 0.07%/year (based on ADOPT data) and 0.035% (assumed extra 50% function preserved) were simulated for the period after achieving the goal; for the control group a normal 0.15%/year decay curve was simulated. Bases on an assumed cost of US$4.86/day for the DPP-IV inhibitor, the incremental cost-effectiveness ratio (ICER) for the DPP-IV inhibitor versus no treatment was US$67 680/QALY gained with the 0.07%/year decay curve; the ICER was reduced to $US50 947/QALY gained for the 0.035%/year curve cohort. Tunis SL, et al. Long-term economic value of a hypothetical DPP-4 inhibitor for the treatment of type 2 diabetes mellitus: the potential impact of the preservation of beta-cell function. Diabetes 57 (Suppl. 1): 345 (plus poster) abstr. 1211-P, Jun 2008 801085170 1 PharmacoEconomics & Outcomes News 28 Jun 2008 No. 556 1173-5503/10/0556-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of DPP-IV inhibitors could be cost-effective for T2DM
PharmacoEconomics & Outcomes News 556 - 28 Jun 2008
DPP-IV inhibitors could be cost-effective for T2DM
Because of the potential for DPP-IV inhibitors[CD-26 antigen agonists] to preserve β-cell function,US-based researchers evaluated the 35-year costeffectiveness of a hypothetical DPP-IV inhibitor versusno treatment, in patients with type 2 diabetes. Theirfindings were presented at the 68th Annual ScientificSessions of the American Diabetes Association
A mean baseline HbA1c of 7.6% was assumed in thebase case simulation, with a reduction in HbA1c of 0.6%for the DPP-IV inhibitor but no improvement with notreatment. β-cell function decay curves of 0.07%/year(based on ADOPT data) and 0.035% (assumed extra50% function preserved) were simulated for the periodafter achieving the goal; for the control group a normal0.15%/year decay curve was simulated.
Bases on an assumed cost of US$4.86/day for theDPP-IV inhibitor, the incremental cost-effectivenessratio (ICER) for the DPP-IV inhibitor versus no treatmentwas US$67 680/QALY gained with the 0.07%/year decaycurve; the ICER was reduced to $US50 947/QALY gainedfor the 0.035%/year curve cohort.Tunis SL, et al. Long-term economic value of a hypothetical DPP-4 inhibitor forthe treatment of type 2 diabetes mellitus: the potential impact of the preservationof beta-cell function. Diabetes 57 (Suppl. 1): 345 (plus poster) abstr. 1211-P, Jun2008 801085170
1
PharmacoEconomics & Outcomes News 28 Jun 2008 No. 5561173-5503/10/0556-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
